CD274 and lung cancer: Since the ground-breaking discovery of checkpoint blockade through anti-PD-1– and anti-PD-L1–based immunotherapy and the successful application of these immunotherapies in lung cancer, melanoma, etc., continuous efforts have focused on methods for identifying the patients most likely to respond to immunotherapy.